{"query":"858 Therapeutics Jeffrey Stafford CEO supply chain logistics","follow_up_questions":null,"answer":null,"images":[],"results":[{"url":"https://www.crunchbase.com/person/jeffrey-stafford","title":"Jeffrey Stafford - CEO and Founder @ 858 Therapeutics - Crunchbase","content":"Jeffrey Stafford is the Chief Executive Officer and Founder of 858 Therapeutics.","score":0.9999678,"raw_content":null},{"url":"https://theorg.com/org/858-therapeutics/org-chart/jeffrey-stafford","title":"Jeffrey Stafford - CEO at 858 Therapeutics - The Org","content":"Dr. Jeffrey Stafford is the CEO and cofounder of 858 Therapeutics. Jeff started his drug discovery career at Glaxo Research Institute in 1991.","score":0.9999517,"raw_content":null},{"url":"https://firstwordpharma.com/story/5812024","title":"858 Therapeutics Expands Leadership Team to Support Transition ...","content":"... Jeffrey Stafford, Ph.D., CEO of 858 Therapeutics. The company's lead asset, ETX-19477, is a small molecule inhibitor of PARG, a","score":0.99983776,"raw_content":null},{"url":"https://www.versantventures.com/system/uploads/fae/file/asset/98/858_Therapeutics_Launches_with_Proven_Team_and__60_Million_Series_A_Financing___Business_Wire.pdf","title":"[PDF] 858 Therapeutics Launches with Proven Team and $60 Million ...","content":"858’s founding team includes CEO Jeffrey Stafford, Ph.D., CSO James Veal, Ph.D., and VP of Biology Gretchen Bain, Ph.D. They previously held leadership roles at three other San Diego-based discovery companies co-founded by Versant including Jecure Therapeutics, Quanticel Pharmaceuticals and Amira Pharmaceuticals. Until now, however, it has been challenging to address many of these enzyme targets because of a dearth of assays and challenges in creating chemical 858 Therapeutics Launches with Proven Team and $60 Million Series A Financing -- Serial entrepreneurs Jeff Stafford, Jim Veal, Gretchen Bain form another San Diego-based discovery company with Versant Ventures ---- Lead cancer drug discovery programs in the fields of RNA metabolism and innate immunity --TM TM matter with drug-like properties. “We look forward to working with management to translate these recent discoveries into a pipeline of important therapeutics.” About 858 Therapeutics 858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecules directed against novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.","score":0.9998118,"raw_content":null},{"url":"https://www.linkedin.com/in/jeffrey-stafford-7b878010","title":"Jeffrey Stafford - 858 Therapeutics, Inc. | LinkedIn","content":"Experience: 858 Therapeutics, Inc. · Education: Cornell University · Location: San Diego County · 500+ connections on LinkedIn. View Jeffrey Stafford's","score":0.9995005,"raw_content":null}],"response_time":0.73,"request_id":"2d2e9b68-895c-4136-b3ce-259df79d6140"}